“Patients First.”
Evgeny Kobin is a globally experienced biopharmaceutical commercial leader whose career spans more than two decades across oncology, rare diseases, diagnostics, radiopharmaceuticals, and market-shaping global launches. Guided by the principle “Patients First,” he has built a reputation for uniting scientific rigor with commercial acumen to elevate breakthrough therapies from concept to global impact. His work sits at the intersection of clinical insight, strategic foresight, and disciplined execution, enabling companies to navigate complex therapeutic landscapes and bringing transformative treatments to patients worldwide.
From the earliest stages of his career, Dr. Kobin demonstrated a rare capacity to bridge medicine, business strategy, and market dynamics. Beginning in pharmaceutical sales and marketing, he gained firsthand exposure to the needs of clinicians, the pressures of competitive markets, and the realities of patient access. These early experiences shaped his enduring belief that successful commercialization must be grounded in empathy, evidence, and clarity of purpose. Over time, his trajectory evolved from local roles into influential global leadership positions where he helped shape major therapeutic franchises and emerging assets across more than twenty countries.
As he progressed into mid-career leadership roles, Dr. Kobin began shaping commercial strategies for some of the industry’s most complex therapeutic areas. At Novartis, he led commercial strategy and lifecycle planning for Afinitor with a portfolio of nine oncology indications, carried combined billion-dollar potential. His ability to translate emerging science into commercially viable pathways allowed cross-functional teams to align early on trial design, positioning, and launch expectations. This period laid the groundwork for his reputation as a strategic partner to R&D, medical, clinical development, and regulatory affairs—alliances that would define his leadership style throughout subsequent roles.
His transition to Baxter Bioscience marked a meaningful expansion of his global expertise. Leading marketing for a $2.5B hemophilia portfolio of four brands, he introduced a commercial prioritization framework that transformed global decision-making and guided expansion across diverse markets. His efforts enabled double-digit annual growth, secured multiple high-value tenders, and improved global access for hemophilia patients. These accomplishments further reinforced his belief that well-designed strategy —paired with strong stakeholder alignment —can create lasting impact across entire therapeutic categories.
Dr. Kobin continued refining his leadership approach working on commercial planning for a biosimilar oncology and immunology portfolio with small pharmaceutical outfit where he. He built forecasting models, brand identities, and competitive frameworks that positioned the company for sustained growth in a rapidly evolving landscape of biosimilars. His work reflected a nuanced understanding of global pricing pressures, regulatory complexity, and shifting standards of care, skills that would become invaluable in later roles focused on highly specialized and rare disease markets.
His tenure at Eli Lilly marked another pivotal chapter, where he served as global and U.S. launch lead for CYRAMZA in bladder cancer—one of the most competitive and fast-moving oncology arenas. Dr. Kobin built launch roadmaps, orchestrated global market assessments, and identified more than $100M in commercial opportunity using a combination of advisory insights, demand studies, and HCP research. His ability to navigate immuno-oncology competition while unifying global and regional stakeholders showcased his strength as a launch architect capable of steering large organizations through complex, multi-market strategies.
Dr. Kobin’s leadership at Amicus Therapeutics further solidified his expertise in rare disease commercialization. As Global Brand Leader for GALAFOLD, he directed strategy for a $365M franchise and delivered consistent double-digit growth. His initiatives included advancing diagnostic partnerships, establishing global digital engagement platforms, and designing company processes that strengthened planning alignment across more than twenty countries. His work not only accelerated patient identification and treatment but also reinforced the profound influence of integrated brand leadership on a therapy’s global reach.
Most recently, Dr. Kobin has served as Head of Commercialization for ZIRCAIX and TLX250Tx at Telix Pharmaceuticals, where his contributions reflect the full breadth of his scientific, commercial, and strategic capabilities. Leading the global commercialization of a first-in-class radiopharmaceutical bioconjugate diagnostic–therapeutic pair, he shaped brand strategy, guided market assessment, aligned early development pathways, and built multi-year roadmaps to unlock nearly $1B in combined commercial potential. His work included informing FDA and EMA interactions, designing launch readiness frameworks, orchestrating distribution strategies, and overseeing life-cycle planning built on real-world evidence generation. These efforts demonstrate a mature and forward-leaning approach to commercialization of emerging radipharmaceuticals’—one that integrates regulatory insight, scientific evolution, and the practical realities of global market uptake.
Throughout his career, Dr. Kobin has maintained a global mindset shaped by extensive work across Europe, the U.S., LATAM, Canada, APAC, and the UK. Fluent in both English and Russian, he brings cultural awareness and international leadership experience that strengthen his ability to guide cross-regional teams and advise organizations with multinational ambitions. His medical training in urology, paired with an MBA from the Kellogg School of Management, uniquely equips him to bridge scientific understanding with data-driven commercial decision-making.
A consistent thread throughout Dr. Kobin’s career is his dedication to elevating teams and enabling collective success. He has influenced countless matrix organizations—spanning R&D, clinical development, medical affairs, market access, HEOR, finance, and regional leadership—by offering clarity, fostering collaboration, and enabling others to operate with precision and purpose. His leadership is marked by humility, intellectual discipline, and an unwavering commitment to improving patient outcomes through thoughtful commercialization.
Today, Dr. Kobin continues to serve as a strategic partner and thought leader for companies seeking to navigate the complexities of oncology, rare diseases, diagnostics, and radiopharmaceutical innovation. With more than thirty years of professional experience, he remains deeply motivated by the opportunity to support clinical-stage companies developing transformative therapies. His mission is rooted in helping organizations overcome scientific, regulatory, and market barriers so that patients ultimately gain access to treatments capable of changing and saving lives.
Character:
Evgeny Kobin exemplifies integrity through his consistent prioritization of patient needs and his ability to make decisions grounded in both ethics and clinical understanding. He approaches challenges with humility, resilience, and a deep respect for the interdisciplinary teams he leads. His unwavering commitment to improving patient care reflects a character built on compassion and responsibility.
Knowledge:
He brings an exceptional command of oncology, rare diseases, global commercialization, and lifecycle strategy supported by extensive experience across major pharmaceutical markets. His medical and business education enables him to synthesize scientific data with market insights to guide effective decision-making. He continuously deepens his expertise, ensuring his strategies remain forward-looking and aligned with evolving standards of care.
Strategic:
Dr. Kobin excels at envisioning long-range opportunities while maintaining the discipline to execute near-term priorities with precision. He builds strategies rooted in rigorous analysis, cross-functional alignment, and a clear understanding of the competitive landscape. His ability to anticipate market shifts and translate complexity into actionable pathways strengthens organizations at pivotal inflection points.
Communication:
He communicates with clarity, empathy, and purpose, ensuring alignment across diverse global stakeholders. His leadership style emphasizes transparent dialogue that empowers teams and drives unified execution. Whether engaging regulatory authorities, scientific leaders, or commercial partners, he conveys insight in a way that inspires confidence and forward momentum.
